Salarius Pharmaceuticals, Inc. (SLRX)
| Market Cap | 31.19M |
| Revenue (ttm) | 4.79M |
| Net Income (ttm) | -7.47M |
| Shares Out | 17.97M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $1.28 |
| Previous Close | $1.35 |
| Change ($) | -0.07 |
| Change (%) | -5.19% |
| Day's Open | 1.37 |
| Day's Range | 1.17 - 1.40 |
| Day's Volume | 2,645,470 |
| 52-Week Range | 0.56 - 3.50 |
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pedia...
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS),...
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, sol...
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pedia...
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, sol...
HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediat...
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET
Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET
HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its C...
Presentations Will Highlight Corporate and Clinical Progress Presentations Will Highlight Corporate and Clinical Progress
Webcast presentation scheduled for Tuesday, September 1, 2020 Webcast presentation scheduled for Tuesday, September 1, 2020
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript
Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas
Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET
New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today an...
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today ...
Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas Pre-Clinical Data and Early Clinical Ob...
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020
Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director Board of Directors Seeks the Election o...
European Patent Office Satisfied Patent Application Meets All Requirements
HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today an...
HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pri...
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study
About SLRX
Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to d... [Read more...]
| Industry Biotechnology | |
| CEO David Arthur | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol SLRX |
Financial Performance
In 2019, SLRX's revenue was $3.47 million, an increase of 77.57% compared to the previous year's $1.95 million. Losses were -$6.94 million, 315.4% more than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.43, which is an increase of 246.09% from the latest price.